ArticleBMC medical imaging2025
Multiparametric MRI characteristics for differentiating primary cancer origin in brain metastases.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Physio-metabolic MRI of oxygen metabolism and neovascularization for differentiating glioblastomas from solitary NSCLC brain metastases.La Radiologia medica · 2026Observational
- Artificial Intelligence-Based MRI Segmentation in Glioblastoma and Single Brain Metastasis: An Exploratory Study of Diagnostic and Prognostic Value.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate identification of primary cancer origin in brain metastases (BMs) is crucial for diagnosis and treatment planning. Identification is challenging, particularly in unknown primary cases. Multiparametric Magnetic Resonance Imaging (MRI) offers non-invasive imaging characteristics as diagnostic clues. This study aimed to investigate the relationship between multiparametric MRI features of BMs and their primary tumor origin.
methodsThis retrospective study included 125 patients with intra-axial brain metastases, classified as breast cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), malignant melanoma, and other cancers. Multiparametric MRI, including T2-FLAIR, contrast-enhanced 3D T1-weighted imaging, apparent diffusion coefficient (ADC) maps, susceptibility-weighted imaging (SWI), and cerebral blood volume (CBV) maps, was performed. Lesion volume, necrotic volume, necrosis ratio, peritumoral edema volume, and edema ratio were measured. 3D Slicer
results291 metastatic lesions from 125 patients were analyzed. NSCLC metastases showed significantly higher necrosis ratios than breast (p < 0.001) and SCLC (p = 0.025) metastases. Malignant melanoma metastases exhibited significantly higher edema ratios than breast (p = 0.001) and SCLC (p = 0.004) metastases. NSCLC metastases also showed a significantly higher edema ratio than breast (p = 0.011) metastases. Mean ADC values were significantly higher in NSCLC metastases compared to all other groups, with an optimal cut-off of ≥ 0.905 mm²/s (AUC: 0.775). Malignant melanoma and SCLC metastases had significantly higher rCBV values than breast cancer metastases. Malignant melanoma metastases consistently showed the highest ITSS scores among all groups, with an optimal cut-off of ≥ 1 (AUC: 0.769). Furthermore, multiple metastases ≤ 0.5 cm³ were significantly associated with breast cancer (p = 0.041). Infratentorial metastases were more prevalent in breast cancer (OR = 2.490, p = 0.001).
conclusionBrain metastases exhibit distinct multiparametric MRI characteristics by primary cancer origin. Breast cancer metastases tend to be smaller, multiple, and infratentorial. NSCLC metastases show greater necrosis and higher ADC values, while melanoma metastases demonstrate higher intratumoral susceptibility. These features offer valuable diagnostic clues for differentiating primary cancer types in patients with brain metastases. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.